Phytoecdysones and the derivatives thereof for use in the treatment of neuromuscular diseases

Patent metadata

Field	Value
Publication number	US-12440500-B2
Application number	US-202017439681-A
Country	US
Kind code	B2
Filing date	Mar 12, 2020
Priority date	Mar 15, 2019
Publication date	Oct 14, 2025
Grant date	Oct 14, 2025

Abstract

Disclosed are 20-hydroxyecdysone and the derivatives thereof, intended for use in the treatment of a neuromuscular disease such as spinal muscular atrophy or amyotrophic lateral sclerosis, or more particularly in the treatment of a specific disorder of the motor neurons causing alterations in the muscular function occurring in the context of these neuromuscular diseases.

First claim

The invention claimed is:

1. A method of treatment of a specific disorder of the motor neurons in mammals suffering from a neuromuscular disease including an alteration of the muscular function due to the specific disorder of the motor neurons, wherein said neuromuscular disease is spinal muscular atrophy (SMA), said method comprising the step of administering to a subject in need thereof an effective dose of a composition comprising at least 20-hydroxyecdysone and/or at least one semi-synthetic derivative of 20-hydroxyecdysone of the general formula (I):

wherein:
V—U is a carbon-carbon single bond and Y is a hydroxyl group or a hydrogen, or V—U is an ethylenic C═C bond;
X is an oxygen;
Q is a carbonyl group;
R 1 is chosen from:
a (C 1 -C 6 )W(C 1 -C 6 ) group;
a (C 1 -C 6 )W(C 1 -C 6 )W(C 1 -C 6 ) group;
a (C 1 -C 6 )W(C 1 -C 6 )CO 2 (C 1 -C 6 ) group;
a (C 1 -C 6 )A group, A representing a heterocycle optionally substituted with a group of the type OH, OMe, (C 1 -C 6 ), N(C 1 -C 6 ), CO 2 (C 1 -C 6 );
a CH 2 Br group;

W being a heteroatom chosen from N, O and S.

2. The method as claimed in claim 1 , wherein the 20-hydroxyecdysone is included in a plant extract or an extract of a plant part, said plant being chosen from plants containing at least 0.5% of 20-hydroxyecdysone by dry weight of said plant, said extract including at least 95% of 20-hydroxyecdysone.

3. The method as claimed in claim 2 , wherein the composition includes remarkably between 0 and 0.05%, by dry weight of the extract, of impurities able to affect the safety, the availability or the efficacy of a pharmaceutical application of said extract.

4. The method according to claim 2 , wherein the plant is chosen from Stemmacantha carthamoides, Cyanotis arachnoidea and Cyanotis vaga.

5. The method according to claim 1 , wherein the alteration of the muscular function is generated by an alteration of the motor neurons function or the degeneration thereof.

6. The method according to claim 1 , wherein the disorder of the motor neurons results from a genetic alteration in mammals suffering from spinal muscular atrophy.

7. The method according to claim 1 , wherein the altered muscular function is that of striated skeletal muscle or of the myocardium.

8. The method according to claim 1 , wherein the alteration of the muscular function is linked to aplasia and/or atrophy.

9. The method according to claim 1 , wherein 20-hydroxyecdysone and/or said at least one semi-synthetic derivative of 20-hydroxyecdysone of the general formula (I) is used to treat at least one genetic alteration responsible for SMA.

10. The method according to claim 1 , wherein spinal muscular atrophy results from a mutation of the gene SMN1.

11. The method according to claim 1 , wherein the treatment of the specific disorder of the motor neurons includes the improvement in motor neuron survival and/or the acceleration in the maturation of the neuromuscular junctions.

12. The method according to claim 1 , wherein 20-hydroxyecdysone and/or said at least one semi-synthetic derivative of 20-hydroxyecdysone of the general formula (I) is administered at a dose comprised between 3 and 15 milligrams per kilogram per day in humans.

13. The method according to claim 1 , wherein 20-hydroxyecdysone and/or said at least one semi-synthetic derivative of 20-hydroxyecdysone of the general formula (I) is administered at a dose of 200 to 1000 mg/day, divided into one or more doses, in human adults, and a dose of 5 to 350 mg/day, divided into one or more doses, in human children or infants.

14. The method according to claim 1 , wherein in the general formula (I):
Y is a hydroxyl group;
R 1 is chosen from:
a (C 1 -C 6 )W(C 1 -C 6 ) group;
a (C 1 -C 6 )W(C 1 -C 6 )W(C 1 -C 6 ) group;
a (C 1 -C 6 )W(C 1 -C 6 )CO 2 (C 1 -C 6 ) group;
a (C 1 -C 6 )A group, A representing a heterocycle optionally substituted with a group of the OH, OMe, (C 1 -C 6 ), N(C 1 -C 6 ), CO 2 (C 1 -C 6 ) type;

W being a heteroatom chosen from N, O and S.

15. The method according to claim 1 , wherein said at least one semi-synthetic derivative of 20-hydroxyecdysone of the general formula (I) is chosen from:
no. 1: (2S,3R,5R,10R,13R,14S,17S)-2,3,14-trihydroxy-10,13-dimethyl-17-(2-morpholinoacetyl)-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one;
no. 2: (2S,3R,5R,10R,13R,14S,17S)-2,3,14-trihydroxy-17-[2-(3-hydroxypyrrolidin-1-yl)acetyl]-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one;
no. 3: (2S,3R,5R,10R,13R,14S,17S)-2,3,14-trihydroxy-17-[2-(4-hydroxy-1-piperidyl)acetyl]-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one;
no. 4: (2S,3R,5R,10R,13R,14S,17S)-2,3,14-trihydroxy-17-[2-[4-(2-hydroxyethyl)-1-piperidyl]acetyl]-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one;
no. 5: (2S,3R,5R,10R,13R,14S,17S)-17-[2-(3-dimethylaminopropyl (methyl)amino)acetyl]-2,3,14-trihydroxy-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one;
no. 6: 2-[2-oxo-2-[(2S,3R,5R,10R,13R,14S,17S)-2,3,14-trihydroxy-10,13-dimethyl-6-oxo-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl]ethyl]ethyl sulfanylacetate;
no. 7: (2S,3R,5R,10R,13R,14S,17S)-17-(2-ethylsulfanylacetyl)-2,3,14-trihydroxy-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one; and
no. 8: (2S,3R,5R,10R,13R,14S,17S)-2,3,14-trihydroxy-17-[2-(2-hydroxyethylsulfanyl)acetyl]-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one.

16. The method according to claim 1 , wherein the at least one semi-synthetic derivative of 20-hydroxyecdysone has the formula (II):

17. The method as claimed in claim 1 , wherein the 20-hydroxyecdysone is included in a plant extract or an extract of a plant part, said plant being chosen from plants containing at least 0.5% of 20-hydroxyecdysone by dry weight of said plant, said extract including at least 97% of 20-hydroxyecdysone.

18. The method according to claim 17 , wherein the plant is chosen from Stemmacantha carthamoides, Cyanotis arachnoidea and Cyanotis vaga.

Assignees

• Biophytis
• Univ Sorbonne

Inventors

• Latil Mathilde
• Dilda Pierre
• LAFONT René
• Veillet Stanislas

Classifications

• A61K31/58

  containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048}) · CPC title

• A61P21/00

  Drugs for disorders of the muscular or neuromuscular system · CPC title

• A61K31/57

  substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone · CPC title

• A61K31/56

  Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids · CPC title

• A61K31/575 Primary

  substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol · CPC title